Initial studies with anti-PD-(L)1 were performed in patients with melanoma (a highly immunogenic tumor ), yielding impressive results [167,168], which support the current use of PD-(L)1 inhibitors as standard of care in advanced melanoma. The gene discussed is CD274; the disease is neoplasm.